Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting.
Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript
10:09pm, Thursday, 27'th Feb 2025
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, Pres
Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates
07:15pm, Thursday, 27'th Feb 2025
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.10 per share a year ago.
Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
04:05pm, Thursday, 27'th Feb 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024.
Castle Biosciences to Participate in Upcoming Investor Conferences
04:30pm, Tuesday, 25'th Feb 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month.
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
12:45pm, Monday, 24'th Feb 2025
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
11:05am, Thursday, 20'th Feb 2025
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
10:55am, Thursday, 20'th Feb 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable,
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii,
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
01:20pm, Wednesday, 12'th Feb 2025
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 12'th Feb 2025
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet
10:55am, Wednesday, 29'th Jan 2025
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 51.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo
4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now
09:10am, Wednesday, 22'nd Jan 2025
Buy these four top-ranked stocks, CSTL, OPFI, GCT and QIFU, with solid net profit margins to enhance your portfolio returns.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of tests for skin cancer through poster presentations at the Maui Derm Ha
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
06:00pm, Sunday, 12'th Jan 2025
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary
